Prescribing Tranylcypromine (Parnate)

Why Tranylcypromine Still Matters

Tranylcypromine (Parnate) is one of the most effective antidepressants ever brought to market, and it sits nearly untouched at the back of the pharmacy. Fewer than one in fifty psychiatrists prescribes MAOIs with any regularity, and a whole generation of clinicians has trained and built careers without ever writing for one. Yet for the patient who has failed four antidepressants, or the patient with atypical depression who sleeps twelve hours and still can't get out of bed, or the one whose life has narrowed to a chair by the window, tranylcypromine is frequently the drug that works when nothing else did.

Its neglect has almost nothing to do with efficacy. MAOIs came up in the 1950s and 1960s, before controlled trials were routine, so their evidence base looks thinner on paper than it is in practice. They carry two frightening interactions, hypertensive crisis and serotonin syndrome, that acquired an outsized, almost mythological reputation. The tyramine diet, drilled into everyone in training, sounds like a life sentence of culinary deprivation. And there is no marketing budget, no rep, and nothing to remind anyone that this old generic exists. The drug fell out of collective muscle memory.

Tranylcypromine is not a first-line agent. It earns its place after multiple failures, and it demands a patient who can partner with you on diet and drug safety. Within that population, though, its response rates are among the best in psychiatry, and the data say the serious events are rare. The tragedy is that thousands of patients who would remit on an MAOI never get offered one, because their prescriber was afraid of a diet.

Part 1: Indications

FDA-Approved Use

• Major depressive disorder, particularly when other antidepressants have failed (treatment-resistant depression).

The Evidence-Based Clinical Uses

Treatment-resistant depression: the core indication. In a classic study of 47 patients with depression refractory to two or more tricyclics, tranylcypromine produced a ~50% response rate, which is remarkable in a population defined by prior failure. MAOIs sit at the later stages of virtually every TRD algorithm, and the mistake most clinicians make is waiting far too long to get there. Once a patient has failed roughly four adequate antidepressant trials, the MAOI conversation isn't exotic; it's overdue.

Atypical depression: where MAOIs may be uniquely good. Atypical features (increased appetite, increased sleep [hypersomnia], leaden paralysis, mood reactivity, and rejection sensitivity) define a subgroup where older MAOIs have historically outperformed tricyclics (2006 meta-analysis, Henkel et al.). The advantage over SSRIs is less clear-cut in modern data, but many clinicians still reach for an MAOI specifically for the sleepy, heavy, appetite-driven atypical presentation that never quite responds to serotonergic agents.

Anxious and agitated depression. Tranylcypromine is used for depression accompanied by prominent anxiety and agitation. If anxiety is the dominant feature, though, phenelzine is the better-evidenced MAOI, with the larger track record in anxiety-spectrum illness (see comparisons below).

Off-label and pilot-data uses. Tranylcypromine and the MAOI class have supportive (if smaller) evidence in:

• Social anxiety disorder: a class strength; phenelzine has a large effect size across 5 RCTs, larger than typically seen with SSRIs.
• Panic disorder: particularly when comorbid with social anxiety.
• Dysthymic disorder: demonstrated efficacy.
• PTSD: pilot data.
• Bulimia: pilot data.

Who Is a Good Candidate

• Patients with treatment-resistant depression after multiple adequate antidepressant trials.
• Patients with atypical features (hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity).
• Patients who can reliably follow dietary and drug restrictions.
• Patients with the cognitive capacity and life stability to partner on safety.

Who Is a Poor Candidate

• Patients unable or unwilling to follow dietary restrictions.
• Active stimulant or cocaine users (hypertensive crisis risk).
• Patients requiring multiple serotonergic agents that can't be stopped.
• Pheochromocytoma (absolute contraindication).
• Uncontrolled hypertension or significant cardiovascular disease (relative; orthostasis and crisis risk).
• Patients who cannot be safely dispensed medication if impulsive-overdose risk is high.

Part 2: Workup and Candidacy

Unlike lithium or the TCAs, tranylcypromine requires no routine drug-level monitoring and no baseline ECG. The workup is safety education and a cardiovascular baseline, not labs.

Baseline Assessment

There are no routine baseline labs and no mandatory ECG. Levels are rarely needed and can be measured only if compliance is in question.

The Washout Before You Start

Treat the washout as part of the workup. Before the first tranylcypromine tablet:

• Taper the prior antidepressant over 1–2 weeks (or stop abruptly for the long-half-life agents), then wait 4 to 5 half-lives of that drug before starting.
• Fluoxetine: because of its long half-life and that of its active metabolite, wait at least 5 weeks.
• Vortioxetine: wait at least 3 weeks; it can be stopped abruptly.
• Other SSRIs, SNRIs and tricyclics: at least 2 weeks after taper.
• Bridge the gap with a benzodiazepine for distress and insomnia if needed.

Part 3: How to Start and Dose

Formulation

Tranylcypromine comes in exactly one size: 10 mg tablets (generic available). There is no extended-release, no liquid, no patch. Having a single strength helps: there's no dose confusion and no formulation switching, and you titrate by counting tablets. The 10 mg strength distinguishes Parnate from phenelzine (Nardil, 15 mg) and matches isocarboxazid (Marplan, 10 mg).

Dosing by Indication

• Major depressive / treatment-resistant depression (FDA-approved): the label's recommended dose is 30 mg/day in divided doses; if response is inadequate, increase by 10 mg/day every 1–3 weeks to the maximum of 60 mg/day (30 mg BID). In real-world practice most prescribers start lower (10 mg/day, or 10 mg BID) and titrate up over the first 1–2 weeks to limit early orthostasis and insomnia. The destination (often 40–60 mg/day in refractory patients) matters more than the exact ramp.
• Atypical depression (off-label): same dose range as MDD (typically 30–60 mg/day); MAOIs are a classic choice for the hypersomnic, hyperphagic, leaden-paralysis phenotype.
• Social anxiety disorder, panic disorder, dysthymia (off-label): the MAOI class is effective here (phenelzine is the better-evidenced MAOI for anxiety-spectrum illness). When tranylcypromine is used, dosing follows the same 30–60 mg/day range titrated to response; there is no separate FDA-sanctioned anxiety-dosing schedule for tranylcypromine.

Starting Dose and Titration

• Label recommended dose: 30 mg/day in divided doses. A common real-world start is lower: 10 mg (one tablet) in the morning, or 10 mg BID (morning and early afternoon), building up to the effective dose over the first week or two. Divided daytime dosing reduces both orthostasis and insomnia.
• Titrate by 10 mg/day every 1–3 weeks as tolerated (the label's increment), watching orthostatic blood pressure at each step. Slow it further if orthostasis emerges; postural hypotension is the rate-limiting side effect.
• A workable schedule: 10 mg BID (20 mg/day) for ~1–2 weeks → 30 mg/day → 40 mg/day by ~week 3–4. Hold at 40 mg for about 2 weeks and assess response before pushing toward 60 mg.
• Avoid late-afternoon/evening dosing where possible: tranylcypromine is often stimulating, and late doses drive insomnia. Keep the last dose to early afternoon.

Target Dose

• Dose-response is real. The most common cause of a "failed" MAOI trial is an inadequate dose. If a patient tolerates the drug but hasn't responded, the answer is usually more, not a switch.
• Divided dosing (BID/TID) is generally preferable to once-daily; it smooths orthostasis. Keep the last dose early to avoid insomnia.
• Maintenance: the label defines no separate maintenance dose. After remission, hold the lowest dose that keeps the patient well, often the same dose that produced the response.

Dose Adjustments and Special Populations

• Geriatric: the label directs cautious dose selection, "usually starting at the low end," with more gradual increases in patients at risk for hypotension. Start 10 mg/day, raise only every ~2 weeks, and target a conservative dose within the usual range (roughly 30–60 mg/day) as tolerated. Orthostatic hypotension, falls, and confusion are the dominant risks; home BP monitoring is essential.
• Renal impairment: the label provides no specific dose adjustment; use caution, since accumulation raises the risk of orthostatic hypotension and toxicity. Reduce the dose and monitor more closely in significant impairment.
• Hepatic impairment: again no labeled dose adjustment; use caution (accumulation risk), with dose reduction and closer monitoring, and be alert for hepatotoxicity as a class effect.
• Pediatric: not approved and not established under 18; safety and efficacy have not been demonstrated, and the dietary-compliance requirement is a practical barrier. Avoid.
• Pregnancy/lactation: no defined dose adjustment; the question is whether to use it at all. MAOIs are rarely first-line in pregnancy (hypertensive-crisis risk, interactions with anesthetics/pressors at delivery, limited data); reserve for the patient whose severe, refractory depression has responded only to tranylcypromine, as an individualized risk/benefit decision with obstetrics. Transfer into breast milk is poorly characterized; use caution with pediatric input.

Stopping and Switching

• Discontinuation: taper by slow, gradual dose reduction (the label's instruction) rather than stopping abruptly; abrupt cessation has been associated with a withdrawal syndrome (agitation, and rarely a discontinuation psychotic delirium). A taper over about 2 weeks is reasonable.
• Washout OFF tranylcypromine (before another MAOI or a serotonergic/contraindicated antidepressant): because inhibition is irreversible, MAO activity returns only as new enzyme is synthesized. The FDA label states at least 1 week should elapse; standard clinical teaching is the more conservative 2 weeks (14 days) for full enzyme regeneration, and the diet/drug restrictions stay in force for that whole window.
• Washout ONTO tranylcypromine (from a prior antidepressant): wait 4 to 5 half-lives of the prior drug: at least 2 weeks for SSRIs, SNRIs and tricyclics, at least 3 weeks for vortioxetine, and a full 5 weeks after fluoxetine (long half-life of drug and active metabolite). For another MAOI, wait at least 1 week or 4–5 half-lives, whichever is longer. Bridge the drug-free gap with a benzodiazepine if needed.

Part 4: Monitoring

Monitoring tranylcypromine is clinical. There are no routine blood levels, no required labs, and no mandatory ECG; you watch blood pressure, tolerability, and adherence to the safety rules.

Blood Pressure

• Check BP at every office visit, sitting and standing (after standing 2–3 minutes).
• Teach home BP monitoring. Have the patient record sitting and standing BP and heart rate, especially during titration.
• You will find yourself watching for orthostatic hypotension far more often than for hypertension: low BP is the common, dose-limiting problem; hypertensive crisis is the rare, dramatic one.

Visit Cadence

• First 2–4 weeks: frequent visits (weekly is reasonable) during titration to track orthostasis, insomnia, and early response.
• Every visit: reinforce dietary and drug restrictions. Teaching them once is not enough; repeat it, and re-check the OTC/supplement list each time.
• Assess weight, sexual function, sleep, and any serotonergic or sympathomimetic exposures at each contact.

What You Do NOT Need

• No routine drug levels (measure only if adherence is in doubt).
• No baseline or routine ECG (unlike TCAs).
• No renal/thyroid/hepatic panels on a schedule; order labs only as clinically indicated.

Part 5: Side Effects and How to Manage Them

As elsewhere in psychiatry, most tranylcypromine side effects are dose-related and manageable, and the common ones (orthostasis, insomnia) are nuisances rather than dangers. The dangerous events (hypertensive crisis, serotonin syndrome) are rare and largely preventable; they are covered separately in Toxicity and Interactions. One advantage tranylcypromine has over its MAOI cousins: less weight gain and less sedation than phenelzine.

Orthostatic Hypotension (the most common problematic effect)

It is more frequent and more troublesome than hypertension, and it's the reason you titrate slowly.

Management:

• Titrate slowly and use divided dosing (BID/TID) rather than a single large dose.
• Increase fluid intake: aim for ~8 glasses of water per day.
• Add dietary salt if not contraindicated.
• Compression/support stockings.
• Lower or remove concurrent antihypertensives where safe.
• Reduce the tranylcypromine dose if orthostasis is limiting.
• Severe/refractory cases: fludrocortisone, roughly 0.1 mg titrated as needed (some sources cite higher PRN regimens); use the lowest effective dose and monitor for edema and supine hypertension.

Insomnia

Tranylcypromine is often stimulating (though some clinicians find it sedating in individual patients; the effect is idiosyncratic). Insomnia is one of the most common adverse reactions in the label's clinical trial data, reported at over 30%.

Management:

• Shift dosing earlier: morning and early afternoon; avoid late-day doses.
• Add a hypnotic if needed. Standard FDA-approved hypnotics (zolpidem, eszopiclone, benzodiazepines, etc.) are compatible, with one exception: doxepin/Silenor is not safe with MAOIs (serotonergic risk).

Weight Gain

A relative strength of tranylcypromine: less weight gain than phenelzine or isocarboxazid. When it occurs, manage with diet, activity, and the usual metabolic counseling.

Sexual Dysfunction

Occurs at a moderate rate, roughly comparable to SSRIs. Options include dose reduction, timing adjustments, or augmentation strategies; some clinicians use bupropion (MAOI-compatible) or a psychostimulant (with monitoring) where appropriate.

Agitation

A moderate amount of agitation/activation can occur, consistent with the drug's stimulating profile. Dose adjustment and timing usually address it; a short-term benzodiazepine can bridge.

Edema

Peripheral edema can occur and is managed with a thiazide diuretic (hydrochlorothiazide); monitor BP, since diuretics compound orthostasis.

Paresthesias

Paresthesia and numbness are listed among the nervous system adverse reactions in the Parnate label. The pyridoxine (vitamin B6) depletion often given as the explanation belongs to the hydrazine MAOIs such as phenelzine; tranylcypromine is not a hydrazine.

Part 6: Toxicity and Boxed Warnings

Unlike the slow, level-dependent toxicity of lithium, tranylcypromine's dangers are two acute, dramatic, and largely preventable events, plus a rare discontinuation phenomenon.

1. Hypertensive Crisis (the "cheese reaction")

Mechanism. MAOIs block the breakdown of dietary tyramine in the gut. Tyramine floods the circulation, displaces norepinephrine from nerve terminals, and, layered on top of the MAOI-driven accumulation of norepinephrine, produces a "double whammy" surge in blood pressure. Tranylcypromine's amphetamine-like structure makes it the classic MAOI most prone to this reaction with tyramine and adrenergic agents.

What the patient feels. Sudden, severe headache; patients describe it as their "head going to split." It may be accompanied by neck stiffness, palpitations, sweating, and nausea. Anecdotally, some patients report headaches in the late afternoon with no obvious trigger.

Acute management:

• Nifedipine 10 mg immediate-release: bite/chew and swallow; repeat in 30 minutes if no relief. This is the "amulet" strategy: patients carry it and can act faster than an ED visit would allow.
• Labetalol is an alternative in a monitored setting.
• Chlorpromazine 50 mg is an older option (effective but sedating, with ~24 hours of malaise, less favored).
• Do NOT use phentolamine reflexively as an outpatient move: too aggressive for self-management.
• A caution on the ED: patients who present to a waiting room often find symptoms and BP normalizing on their own before they're seen. The crisis is frequently self-limited once tyramine clears, which is why patient-carried nifedipine and reassurance matter.

Prevention is the whole job: the tyramine diet plus avoidance of sympathomimetics (below).

2. Serotonin Syndrome

Mechanism. Combining an MAOI with a serotonergic agent produces excess synaptic serotonin: agitation, hyperthermia, clonus, rigidity, autonomic instability, and, at the extreme, death. This risk is more common and more severe with MAOIs than with any other drug class.

Prevention: honor the serotonergic no-fly list and the washout windows (see Interactions). This is a preventable event.

3. Discontinuation Psychotic Delirium (rare)

Abrupt discontinuation of tranylcypromine can, rarely, trigger a psychotic delirium. This is uncommon but real, and it's the reason you taper rather than stop abruptly (see Discontinuation).

Overdose

Part 7: Drug and Dietary Interactions

These lists are the core of MAOI safety. Master them and the drug is safe; ignore them and it is dangerous. Teach them, write them down, and re-check them at every visit.

The Serotonergic No-Fly List (Serotonin Syndrome Risk)

Absolutely contraindicated, do not combine:

• SSRIs and SNRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, etc.)
• Clomipramine: the one TCA that is clearly dangerous (highly serotonergic).
• Meperidine (Demerol): a classic, potentially fatal combination.
• Dextromethorphan: hidden in countless OTC cough/cold products.
• St. John's wort and L-tryptophan.
• Doxepin/Silenor as a hypnotic.
• Ziprasidone: the GEODON label contraindicates concomitant MAOIs, or use within 14 days of stopping one.
• Use only with caution/expert monitoring: buspirone, carbamazepine, cyclobenzaprine, and triptans carry theoretical-to-real serotonergic additivity; generally avoid or monitor closely.

The Sympathomimetic / Hypertensive-Crisis List

Avoid, can precipitate hypertensive crisis:

• OTC decongestants: pseudoephedrine and phenylephrine (in cold/flu/allergy products).
• Cocaine, amphetamines, MDMA (drugs of abuse).
• Other adrenergic/sympathomimetic agents.

The Tyramine Diet: Shorter Than You Were Taught

Most historical diet lists predate accurate tyramine measurement and are dramatically over-inclusive. The modern, evidence-based restriction is a short list of high-tyramine foods.

Combinations That Are Safe (and Useful)

Some combinations are allowed. In expert hands, these are used with tranylcypromine:

• Bupropion: non-serotonergic; safe.
• Mirtazapine: reported safe.
• Certain sedating tricyclics (trimipramine, amitriptyline): reported safe in clinical practice, though caution and expertise are warranted.
• Trazodone: officially contraindicated, but Dr. Cole and colleagues treated ~80 patients with low-dose trazodone atop an MAOI for sleep without incident; used off-label in experienced hands.
• Psychostimulants (methylphenidate, dextroamphetamine): despite the theoretical hypertensive concern, experienced clinicians (Dr. Cole) have used them without hypertensive crisis, in particular to treat MAOI-induced afternoon sleepiness. Use with caution and monitoring.

Augmentation Strategies (When the MAOI Alone Isn't Enough)

• Lithium: the augmentation strategy with the best evidence; a natural pairing for MAOI partial responders.
• Second-generation antipsychotics: usable except ziprasidone.
• Psychostimulants: carefully monitored.
• Trazodone: for sleep, off-label, expert hands.
• Do not augment with SSRIs, SNRIs, or clomipramine: serotonin syndrome.

Surgery and Anesthesia

MAOIs interact with anesthetic and pain agents (especially meperidine and sympathomimetic pressors). Any surgery or procedure requires the anesthesia team to know the patient is on an MAOI; this is what the wallet card is for. Historically MAOIs were stopped before surgery, but with modern anesthesia many procedures can proceed safely with appropriate agent selection; coordinate rather than reflexively discontinue.

Part 8: Special Populations

Pregnancy

Limited safety data: MAOIs are old and poorly studied in pregnancy. They are generally avoided when safer, better-characterized alternatives exist. There are specific concerns about hypertensive effects and drug interactions during labor and delivery (anesthetics, pressors). If a patient's severe, treatment-resistant depression has only ever responded to tranylcypromine, the decision becomes an individualized risk/benefit discussion in coordination with obstetrics, but for most patients, a better-studied agent is preferred in pregnancy.

Lactation

Transfer into breast milk is not well characterized. Given the unknowns and the potential for infant exposure, caution is warranted; this is a benefit-versus-risk decision with pediatric input, and generally not a first choice during breastfeeding.

Elderly

• Orthostatic hypotension is the dominant concern: falls, fractures, cerebral/cardiac ischemia, and confusion.
• Start low, titrate more slowly (some geriatric experts raise the dose only every ~2 weeks), targeting a conservative dose within the usual range (roughly 30 to 60 mg/day) as tolerated.
• Home BP monitoring is essential.
• Tranylcypromine is still a legitimate option in geriatric TRD (the same efficacy that makes it valuable in younger refractory patients applies here), provided orthostasis is respected.

Renal Impairment

Accumulation risk raises the likelihood of orthostatic hypotension and toxicity. Dose reduction and closer monitoring are prudent.

Hepatic Impairment

Also an accumulation risk. Reduce the dose and monitor closely.

Pediatric

Not typically used in children or adolescents: limited safety and efficacy data, and the dietary-compliance requirement is a practical barrier in this age group.

Part 9: Discontinuation and Switching

Stopping Tranylcypromine

• Taper slowly, over about 2 weeks. Do not stop abruptly; rare cases of abrupt-discontinuation psychotic delirium are the reason.
• After stopping, wait a full 2 weeks before lifting dietary/drug restrictions or starting a new (especially serotonergic) antidepressant. The enzyme inhibition is irreversible: MAO activity recovers only as the body synthesizes new enzyme, which takes about 1–2 weeks. Until then, the patient is still functionally "on" an MAOI even though they've stopped the pills; the diet and drug rules stay in force.

Switching

Onto tranylcypromine (from another antidepressant): taper 1–2 weeks, then wait 4 to 5 half-lives: at least 5 weeks for fluoxetine, at least 3 weeks for vortioxetine, at least 2 weeks for SSRIs, SNRIs and tricyclics. Bridge with a benzodiazepine.

Off tranylcypromine (to another antidepressant): taper over ~2 weeks, then wait the full 2 weeks for enzyme recovery before introducing the next agent.

Part 10: Tranylcypromine vs the Alternatives

Within the MAOI Class

vs Phenelzine (Nardil). These are the two most-used oral MAOIs, and the choice between them usually rests on profile:

• Tranylcypromine: less sedation, less weight gain, more likely to be activating/cause insomnia, and higher hypertensive risk with tyramine/adrenergics (amphetamine-like structure). Favored for apathetic, lethargic, anergic depression.
• Phenelzine: more sedating, more weight gain, more sexual dysfunction, but more anxiolytic and better-evidenced for anxiety-spectrum illness (social anxiety, panic) and best-studied for atypical depression; also the most affordable MAOI.
• Rule of thumb: Parnate for apathy and lethargy; Nardil for anxiety and agitation.

vs Isocarboxazid (Marplan). Similar in form (10 mg tablets, up to 60 mg/day) and roughly equivalent efficacy to Parnate/Nardil; reportedly better tolerated than phenelzine in some studies. Reacquired and relaunched in the US by Validus in 2007 but relatively expensive (~$3/tablet). Reasonable if a patient has a prior good response or you can source it affordably.

vs Selegiline transdermal (Emsam). The odd one out among MAOIs:

• At the 6 mg/24h patch, NO dietary restrictions are required (the transdermal route bypasses gut MAO, so tyramine handling is preserved).
• Much cleaner side-effect profile: minimal weight gain, sedation, and sexual dysfunction.
• The catch: at 9–12 mg, dietary restrictions return, and Emsam lacks the efficacy data in TRD and atypical depression that the oral MAOIs have. For your hardest refractory cases, the oral drugs remain better supported. Emsam is the option for a diet-noncompliant or side-effect-sensitive patient. It isn't the heavy hitter you want for stage-4 TRD.

vs Moclobemide (not available in US). Reversible, MAO-A-selective, no meaningful dietary restrictions, but reportedly less effective than the irreversible non-selective agents, and unavailable in the United States anyway.

Against the Broader Antidepressant Field

Tranylcypromine is a rescue drug. It competes with augmentation, TMS, ECT, ketamine/esketamine, and the other stage-4 options for the patient who has already failed the standard agents, not with SSRIs for first-line use. In that setting, its response rates in treatment-resistant and atypical depression are strong, its cost is trivial (generic), and it reaches patients whom serotonergic drugs never touched. The patient pays for it with the diet, the drug list, and the washouts, a real but learnable price.

So why is it underused? Only ~2% of psychiatrists prescribe MAOIs regularly. The reasons are the 1960s reputation, the diet mythology, unfamiliarity bred by a generation of training without hands-on MAOI experience, and the absence of any marketing. None of these are clinical reasons. For the right patient, tranylcypromine belongs earlier in the algorithm than most clinicians place it.

Mechanism

Tranylcypromine is a non-selective, irreversible inhibitor of both MAO-A and MAO-B. By knocking out these enzymes, it blocks the breakdown of norepinephrine, serotonin, and dopamine, raising synaptic levels of all three. Among the classic MAOIs, tranylcypromine has the strongest dopaminergic effect, which likely contributes to its activating, pro-motivational quality and its usefulness in anergic, apathetic depression.

Structurally, tranylcypromine is amphetamine-like, which explains both its stimulating clinical profile and its heightened tendency toward hypertensive reactions with tyramine and adrenergic agents. Because the enzyme inhibition is irreversible, restored MAO activity depends on synthesizing new enzyme, hence the ~2-week recovery period after discontinuation, during which the interaction cautions persist.

The Bedside Cheat Sheet